收费全文 | 177篇 |
免费 | 9篇 |
财政金融 | 52篇 |
工业经济 | 15篇 |
计划管理 | 23篇 |
经济学 | 34篇 |
综合类 | 1篇 |
运输经济 | 9篇 |
旅游经济 | 8篇 |
贸易经济 | 24篇 |
农业经济 | 5篇 |
经济概况 | 15篇 |
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 7篇 |
2019年 | 2篇 |
2018年 | 11篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 5篇 |
2014年 | 8篇 |
2013年 | 34篇 |
2012年 | 11篇 |
2011年 | 4篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 4篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 1篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 2篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
Methods: A previously published Markov model was adapted using Brazil-specific unit costs to compare the costs and outcomes of the addition of omalizumab to standard-of-care therapy vs standard-of-care therapy alone. Model inputs were largely based on the eXpeRience study. Costs and health outcomes were calculated for lifetime-years and were annually discounted at 5%. Both one-way and probabilistic sensitivity analyses were performed.
Results: An additional cost of R$280,400 for 5.20 additional quality-adjusted life-years was estimated with the addition of omalizumab to standard-of-care therapy, resulting in an incremental cost-effectiveness ratio of R$53,890. One-way sensitivity analysis indicated that discount rates, standard-of-care therapy exacerbation rates, and exacerbation-related mortality rates had the largest impact on incremental cost-effectiveness ratios.
Limitations: Assumptions of lifetime treatment adherence and rate of future exacerbations, independent of previous events, might affect the findings. The lack of Brazilian patients in the eXpeRience study may affect the findings, although sample size and baseline characteristics suggest that the modeled population closely resembles Brazilian severe allergic asthma patients.
Conclusion: Results indicate that omalizumab as an add-on therapy is more cost-effective than standard-of-care therapy alone for Brazilian patients with uncontrolled severe allergic asthma, based on the World Health Organization’s cost-effectiveness threshold of up to 3-times the gross domestic product. 相似文献